13F Holdings
中文EN

IMNM Immunome Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1472012 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-63.3%
TTM net income YoY-9.5%
TTM EPS YoY20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,947.9%
Net margin-5,593.8%
FCF margin-5,118.9%
EBITDA margin-5,886.7%

Returns

ROE-50.1%
ROA-46.7%
ROIC (approx.)-679.8%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets5.0%
Debt / equity0.00x
Current ratio21.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue224.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.94M$9.04M$14.02M——
R&D expense$177.29M$129.54M$23.09M$23.27M$14.11M
SG&A expense$43.77M$32.95M$19.66M$13.63M$11.09M
Operating income-$224.11M-$305.80M-$109.53M-$36.90M-$25.20M
Income tax$0$0$0$0$0
Net income-$212.39M-$292.96M-$106.81M-$36.90M-$24.71M
EBITDA-$221.65M-$304.23M-$109.07M-$36.48M-$24.45M
EPS (basic)-2.43-5.00-5.38-3.09-2.14
EPS (diluted)-2.43-5.00-5.38-3.09-2.14
Weighted avg. shares (diluted)87.35M58.64M19.84M12.13M11.54M
Banking
Net interest income$11.72M$12.84M$2.72M$5,000-$10,000
Balance sheet
Cash & equivalents$653.48M$143.45M$98.78M$20.42M$49.33M
Short-term investments$0$73.95M$39.46M——
Current assets$660.78M$221.34M$144.70M$22.65M$56.64M
PP&E, net$14.64M$10.11M$2.07M$681,000$855,000
Total assets$683.19M$240.24M$148.54M$24.05M$57.92M
Current liabilities$44.99M$54.31M$21.83M$7.33M$9.73M
Total liabilities$48.84M$59.08M$28.66M$7.39M$9.74M
Shareholders' equity$634.34M$181.16M$119.88M$16.65M$48.19M
Shares outstanding113.13M64.46M43.25M12.13M12.11M
Cash flow statement
Operating cash flow-$190.92M-$110.79M-$7.57M-$28.69M-$18.23M
Capital expenditure$9.69M$7.17M$831,000$248,000$79,000
Free cash flow-$200.60M-$117.97M-$8.40M-$28.94M-$18.30M
Investing cash flow$60.80M-$85.06M-$30.48M-$248,000-$79,000
Financing cash flow$640.36M$240.53M$116.41M$32,000$27.77M
Depreciation & amortization$2.47M$1.57M$457,000$422,000$755,000
Stock-based compensation$25.69M$15.75M$6.22M$5.33M$3.45M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.